Company news

Vanda Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

July 30, 2025

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

July 22, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

June 9, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

May 26, 2025

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

May 15, 2025

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

May 6, 2025

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

May 4, 2025

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

May 1, 2025

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

April 23, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

April 6, 2025

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

March 30, 2025

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

February 23, 2025

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

February 12, 2025

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

February 4, 2025

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

February 2, 2025

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

January 26, 2025

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

January 7, 2025

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

December 19, 2024

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

November 11, 2024

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

November 5, 2024

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

October 29, 2024

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

October 13, 2024

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

September 18, 2024

Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference

September 10, 2024

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

September 3, 2024

Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference

August 28, 2024

Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results

July 30, 2024

Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024

July 25, 2024

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex

June 30, 2024

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders

June 18, 2024

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak

June 12, 2024

Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.

June 5, 2024

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference

May 29, 2024

Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®

May 29, 2024

Vanda Pharmaceuticals Announces Presentations at SLEEP 2024

May 28, 2024

Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders

May 23, 2024

Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness

May 14, 2024

Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results

May 7, 2024

Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024

April 29, 2024

Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation

April 21, 2024

Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak

April 16, 2024

Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

April 16, 2024

Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

April 1, 2024

Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia

March 5, 2024

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

February 6, 2024

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024

January 30, 2024

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis

January 30, 2024

Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024

January 28, 2024

Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepato...

January 24, 2024

Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.

January 24, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.